Castellani P, Dorcaratto A, Siri A, Zardi L, Viale G L
Department of Neurosurgery, University of Genoa Medical School, Italy.
Acta Neurochir (Wien). 1995;136(1-2):44-50. doi: 10.1007/BF01411434.
Using a monoclonal antibody specific for human tenascin (TN), 180 intracranial growths were immunohistochemically studied. In 69 cases of meningioma, neoplastic cells were negative, with some positivity being observed only in the perivascular and the supporting stroma, especially in anaplastic meningiomas. In 57 cases of glioma different degrees of reactivity occurred in both the cellular conglomerates and the stromal components of the tumours. A higher variability in reactivity was observed in anaplastic astrocytomas and glioblastomas. The most constant finding of the study was the staining of the stroma, which was observed in all types of growths, including metastasis, abscess and tuberculoma. The results are consistent with the hypothesis that tenascin is a stromal marker rather than a true marker of malignant tumours. The heterogeneous distribution of TN in anaplastic gliomas may be a factor in the variable response to treatment with radiolabelled anti-TN monoclonal antibodies.
使用一种对人腱生蛋白(TN)具有特异性的单克隆抗体,对180例颅内肿瘤进行了免疫组织化学研究。在69例脑膜瘤中,肿瘤细胞呈阴性,仅在血管周围和支持性基质中观察到一些阳性反应,尤其是在间变性脑膜瘤中。在57例胶质瘤中,肿瘤的细胞团块和基质成分均出现了不同程度的反应性。在间变性星形细胞瘤和胶质母细胞瘤中观察到更高的反应性变异性。该研究最一致的发现是基质染色,在所有类型的肿瘤中均观察到,包括转移瘤、脓肿和结核瘤。结果与腱生蛋白是一种基质标志物而非恶性肿瘤真正标志物的假设一致。TN在间变性胶质瘤中的异质性分布可能是导致对放射性标记抗TN单克隆抗体治疗反应可变的一个因素。